Xeris Biopharma Holdings, Inc. (XERS) stock
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.99+0.19 (+1.13%)
Close on Nov 18, 2026Market cap $3.10BP/E –Yield –
Xeris Biopharma price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Xeris Biopharma's price to sales ratio was 8.5× on Nov 11, 2026, against 4.5× a year earlier. Over the last 5 years it ranged from 1.5× to 8.5×, with a median of 2.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 8.5× | +3.7 |
| 2025 | Dec 31, 2025 | 4.9× | +2.2 |
| 2024 | Dec 31, 2024 | 2.7× | +0.6 |
| 2023 | Dec 29, 2023 | 2.1× | +0.3 |
| 2022 | Dec 30, 2022 | 1.8× | −3.6 |
| 2021 | Dec 31, 2021 | 5.5× | – |
See a number that looks wrong?